Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

'Developing a coronavirus vaccine is of utmost importance'

In an exclusive interview with Dhaka Tribune's Fahim Reza Shovon, Prof Dr SM Abdur Rahman, dean of pharmacy at Dhaka University, and a member of Protocol Trial Advisory Committee for medicine in Bangladesh, shares his thoughts and opinions on possible vaccines, medicines, research, and overall coordination to tackle the Covid-19 crisis in Bangladesh

Update : 13 May 2020, 06:49 PM

The world is facing unprecedented challenges due to the Covid-19 pandemic. The disease - caused by a new strain of coronavirus - originated from China’s Hubei province and has spread across the world.

Like the other countries, Bangladesh is also going through tough times as a consequence of the pandemic.

Prof Dr SM Abdur Rahman, dean of the pharmacy faculty at Dhaka University, shared his thoughts on possible solutions to the ongoing pandemic.

Dr Rahman, who is also a member of Protocol Trial Advisory Committee for medicine in the country, reflected on what had been happening in the international arena, and the search for vaccines and effective medicines to beat the pandemic.

Vaccine trials

Developing a coronavirus vaccine is of utmost importance, and a possible solution may well be found after the development of a vaccine.

At least four vaccines are on clinical trial at present, while over a hundred facilities are engaged in trying to develop a vaccine, Dr Rahman said.

The German vaccine candidate BNT162 was approved to begin human trials in the US.

"Another vaccine may come from the team of Oxford University scientists, who brought us the Ebola vaccine earlier," he told Dhaka Tribune. "Scientists are mostly confident about its result. It was administered to two healthy people, and they were kept under observation to see if there were any safety concerns or side effects like physiological abnormality. The dosage levels were checked as well."

Starting from the trial phase to manufacturing, the whole vaccine development process takes at least five years. However, scientists are considering the present as an emergency priority.

Search for a cure

In the developed countries, it takes a minimum of 10 years to get a medicine ready for use after 16 procedural stages have been gone through.

This is why scientists across the globe are interested in finding a cure from the existing drugs which are already permitted for use, including Remdesivir, Azithromycin, Favipiravir, and Ivermactin. These have been proven to be safe and have already been used to combat Ebola, malaria, etc.

Despite giving some initial hope, scientists have realized that conditions of Covid-19 patients worsened during clinical trials of Hydroxychloroquine, which also proved to be harmful for cardiac patients, Dr Rahman said.

Favipiravir giving hope

Favipiravir, produced by two Bangladeshi pharmaceutical companies, has yet to go into clinical trial. But some doctors have been using it for treating Covid-19 patients for a week, following approval from the Directorate General of Drug Administration (DGDA).

Hospitals, including the Combined Military Hospital (CMH) and Dhaka Medical College Hospital (DMCH), have used the drug and obtained some positive results. Fourteen patients in the CMH have already recovered after it was used on them.

"We can know more about its effectiveness after the clinical trial, which may take seven more days to commence," Dr Rahman told Dhaka Tribune.

The protocol of another medicine, Ivermactin, has been submitted. It may also be added to the list of medicines used to treat Covid-19 patients.

Research can pave the way for going forward

The strain of the virus is changing and formations have been observed to vary in different places. Research has to be conducted based on these situations as mutations are also taking place, Dr Rahman said.

Research based on science, genes, nutrition, information and communication technology, social science and financial conditions can also be conducted from different perspectives.

"We are assuming that Covid-19 entered Bangladesh from Italy. It could be the United States or Saudi Arabia, too, from where it came to the country. We have to do genome sequencing of the virus immediately to know the exact strain," he told Dhaka Tribune.

"We can take proper steps after sorting it out. I urge the Bangladeshi researchers to be proactive in finding the root of the new strains."

The need for coordination

"I urge everyone concerned to strengthen coordination during the overall process, starting from sample collection. There are doubts in people’s minds as to why only hundreds are turning out to be Covid-19 positive despite more than 5,000 suspected samples being tested every day," Dr Rahman told Dhaka Tribune.

Real time reverse transcription–polymerase chain reaction (rt-PCR) will not give inaccurate results. If there is a mistake, it may have been made during sample collection, he added.

The positivity rate may be low because of that. The rt-PCR test may not have been able to verify some samples if there was a mistake in the collection process.

Notably, the test positivity rate compared to the number of total tests conducted is  below 12%. As of May 10, a total number of 1,22,657 tests have been done while 14,657 cases were found to be Covid-19 positive.

"As Dr Saif Ullah Munshi, chairman of the virology department at Bangabandhu Sheikh Mujib Medical University said, the tests we are doing now can only show real results up to 70%. So we cannot say if the other 30% is positive or negative," Dr Rahman said.

"I would urge the authorities to start rapid testing, using blood samples to deal with the confusion."

Rapid testing can be applied on patients who have already tested positive and also on those who were not tested further after testing negative once, but are suspected to be positive.

The Institute of Epidemiology, Disease Control and Research (IEDCR) and the Directorate General of Health Services (DGHS) have to take coordinated steps to tackle the crisis properly, Dr Rahman said.

Top Brokers